Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instituto RosenbuschBUE:ROSE +1.57%37 ROC (Joel Greenblatt) % is 23.92% as of Dec. 2025, which is 253% above its 10-year median of 6.77. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS62.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 982 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 88.09% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Instituto Rosenbusch's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 23.92%.
The historical rank and industry rank for Instituto Rosenbusch's ROC (Joel Greenblatt) % or its related term are showing as below:
BUE:ROSE'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -81.78 Med: 6.77 Max: 63.06
Current: -81.78
During the past 13 years, Instituto Rosenbusch's highest ROC (Joel Greenblatt) % was 63.06%. The lowest was -81.78%. And the median was 6.77%.
BUE:ROSE's ROC (Joel Greenblatt) % is ranked worse than 88.09% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs BUE:ROSE: -81.78
Instituto Rosenbusch's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Instituto Rosenbusch (BUE:ROSE) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Instituto Rosenbusch ROC (Joel Greenblatt) % Related Terms
Instituto Rosenbusch ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch ROC (Joel Greenblatt) % Chart
BUE:ROSE vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's ROC (Joel Greenblatt) % falls into.
Instituto Rosenbusch ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 23.92% mean?
Instituto Rosenbusch (BUE:ROSE) has a ROC (Joel Greenblatt) % of 23.92% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Instituto Rosenbusch and its competitors. This is 253% above median its historical median of 6.77. According to the industry distribution chart, Instituto Rosenbusch ranks #865 out of 982 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Instituto Rosenbusch's ROC (Joel Greenblatt) % too high?
Instituto Rosenbusch's current ROC (Joel Greenblatt) % of 23.92% is 253% above median its 10-year median of 6.77. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. Instituto Rosenbusch's value of 23.92% is 109.7% above this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #865 out of 982 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #865 out of 982 companies for ROC (Joel Greenblatt) %. This places Instituto Rosenbusch in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.41. Instituto Rosenbusch's value of 23.92% is 109.7% above this benchmark. While the company's 10-year median is 6.77 vs. the industry median of 11.41, Instituto Rosenbusch has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current ROC (Joel Greenblatt) % of 23.92% is 109.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current ROC (Joel Greenblatt) % is 23.92%, which is 253% above median its own 10-year median of 6.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.46, compared to a current price of ARS162.00 — trading 159.4% above its estimated fair value. The current ROC (Joel Greenblatt) % is 23.92%, which is 253% above median its 10-year median of 6.77 and 109.7% above the Drug Manufacturers industry median of 11.41. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current ROC (Joel Greenblatt) % is 23.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS162.00 is trading 159.4% above its estimated GF Value™ of ARS62.46.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
ROC (Joel Greenblatt) %: 23.92% (253% above median its 10-year median of 6.77)
GF Value™: ARS62.46 vs. price of ARS162.00 (159.4% above fair value)
Industry Position: 109.7% above the Drug Manufacturers median (#865 of 982)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
